https://www.germanscienceandtechnologytoday.com/article/905272415-disruptive-futures-institute-s-metaruptions-and-techistentialism-enter-the-global-zeitgeist German Science & Technology Today en PressRelease 2026-04-12T10:42:52+00:00 Disruptive Futures Institute’s Metaruptions and Techistentialism Enter the Global Zeitgeist https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24395028-metaruptions-2026-word-of-the-1920x1920.jpeg https://www.germanscienceandtechnologytoday.com/article/905116581-biontech-and-dualitybio-s-antibody-drug-conjugate-trastuzumab-pamirtecan-demonstrated-clinically-meaningful-efficacy-in-patients-with-her2-expressing German Science & Technology Today en PressRelease 2026-04-11T11:00:00+00:00 BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer https://ml-eu.globenewswire.com/media/b9e2e00e-f790-4d54-a01f-4c85716b01bd/small/190705-biontech-logo-rgb-dark-green-preferred-0-png.png https://www.germanscienceandtechnologytoday.com/article/905116769-biontechs-und-dualitybios-antik-rper-wirkstoff-konjugat-kandidat-trastuzumab-pamirtecan-zeigte-klinisch-relevante-wirksamkeit-bei-patientinnen-mit German Science & Technology Today en PressRelease 2026-04-11T11:00:00+00:00 BioNTechs und DualityBios Antikörper-Wirkstoff-Konjugat-Kandidat Trastuzumab Pamirtecan zeigte klinisch relevante Wirksamkeit bei Patientinnen mit rezidivierendem HER2-exprimierendem Gebärmutterkrebs https://ml-eu.globenewswire.com/media/b9e2e00e-f790-4d54-a01f-4c85716b01bd/small/ https://www.germanscienceandtechnologytoday.com/article/904990337-lithium-ionic-provides-update German Science & Technology Today en PressRelease 2026-04-10T20:52:23+00:00 Lithium Ionic Provides Update https://ml.globenewswire.com/media/3fd96b97-67ea-4de7-9109-3aec2924b948/small/li-lithium-ionic-logo-black-02-png.png